var data={"title":"Fluocinolone (topical): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluocinolone (topical): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluocinolone-topical-drug-information\" class=\"drug drug_general\">see &quot;Fluocinolone (topical): Drug information&quot;</a> and <a href=\"topic.htm?path=fluocinolone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluocinolone (topical): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097444\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Capex;</li>\n      <li>Derma-Smoothe/FS Body;</li>\n      <li>Derma-Smoothe/FS Scalp;</li>\n      <li>Synalar;</li>\n      <li>Synalar (Cream);</li>\n      <li>Synalar (Ointment);</li>\n      <li>Synalar TS;</li>\n      <li>Xilapak</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097445\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Derma-Smoothe/FS;</li>\n      <li>Synalar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501531\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503156\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluocinolone-topical-drug-information\" class=\"drug drug_general\">see &quot;Fluocinolone (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid HPA axis suppression. <b>Note:</b> Therapy should be discontinued when control is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atopic dermatitis, moderate to severe:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Derma-Smoothe/FS body oil (0.01%):  Infants &ge;3 months, Children, and Adolescents: Topical:  Moisten skin; apply a thin film to affected area twice daily; do not use for longer than 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Derma-Smoothe/FS scalp oil (0.01%): Limited data available: Children &ge;2 years and Adolescents: Topical: Apply a thin film to affected area twice daily; do not use longer than 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Synalar cream (0.025%), ointment (0.025%), topical solution (0.01%): Children and Adolescents: Topical: Apply thin layer 2 to 4 times daily to affected area; may use occlusive dressings to manage psoriasis or recalcitrant conditions </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atopic dermatitis;</b> Derma-Smoothe/FS body oil (0.01%): Topical: Apply thin film to affected area 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical: Cream (0.025%), ointment (0.025%), solution (0.01%): Apply a thin layer to affected area 2 to 4 times daily; may use occlusive dressings to manage psoriasis or recalcitrant conditions </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Scalp psoriasis:</b> Derma-Smoothe/FS scalp oil (0.01%): Topical: Massage thoroughly into wet or dampened hair/scalp; cover with shower cap. Leave on overnight (or for at least 4 hours). Remove by washing hair with shampoo and rinsing thoroughly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seborrheic dermatitis of the scalp:</b> Capex shampoo (0.01%): Topical: Apply no more than 1 ounce to scalp once daily; work into lather and allow to remain on scalp for ~5 minutes. Remove from hair and scalp by rinsing thoroughly with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b>  There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100716\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.025% (120 g) [contains cetyl alcohol, edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar (Cream): 0.025% [contains cetyl alcohol, edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar (Ointment): 0.025%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar TS: 0.01% [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xilapak: 0.01% [contains butylparaben, cetyl alcohol, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Derma-Smoothe/FS Body: 0.01% (118.28 mL) [contains isopropyl alcohol, peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Derma-Smoothe/FS Scalp: 0.01% (118.28 mL) [contains isopropyl alcohol, peanut oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (118.28 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.025% (120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025% (15 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Shampoo, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capex: 0.01% (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as acetonide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synalar: 0.01% (60 mL, 90 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097456\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503157\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Synalar cream, ointment, topical solution: Apply sparingly in a thin film; rub in lightly. In hairy sites, the hair should be parted to allow direct contact with the lesion. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capex shampoo: Shake well before use; do not bandage, wrap, or cover treated scalp area unless directed by physician; discard shampoo after 3 months </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Derma-Smoothe/FS (body oil, scalp oil): Do not apply to face or diaper area; avoid application to intertriginous areas (may increase local adverse effects) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097502\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body oil, scalp oil, shampoo: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard shampoo after 2 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, ointment, topical solution: Store between 15&deg;C and 25&deg;C (59&deg;F and 77&deg;F); avoid freezing and excessive heat above 40&deg;C (104&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503151\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body Oil (0.01%) (Derma-Smoothe/FS): Treatment of moderate to severe atopic dermatitis (FDA approved in pediatric patients &ge;3 months); treatment of atopic dermatitis (FDA approved in adults)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream (0.025%), Ointment (0.025%), Topical solution (0.01%) (Synalar):  Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA approved in pediatric patients [age not specified] and adults)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Scalp Oil (0.01%) (Derma-Smoothe/FS): Treatment of  psoriasis of the scalp (FDA approved in adults); has also been used for moderate to severe atopic dermatitis on the scalp </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shampoo (0.01%) (Capex): Treatment of seborrheic dermatitis of the scalp (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097421\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Capex may be confused with Kapidex [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fluocinolone may be confused with fluocinonide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097489\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Cardiovascular: Intracranial hypertension (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Central nervous system: Telangiectasia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Dermatologic: Acneiform eruptions, allergic contact dermatitis, burning, dryness, folliculitis, irritation, itching, hypertrichosis, hypopigmentation, miliaria, perioral dermatitis, skin atrophy, striae</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Endocrine &amp; metabolic: Cushing's syndrome, HPA axis suppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Otic: Ear infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Miscellaneous: Herpes simplex, secondary infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097474\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluocinolone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Viral (eg, herpes, varicella) lesions of the skin; bacterial or fungal skin infections; parasitic infections; skin manifestations relating to tuberculosis or syphilis; eruptions following vaccinations; application to the eye</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097475\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local effects: Local adverse reactions may occur (eg, skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria); may be irreversible. Local adverse reactions are more likely to occur with occlusive and/or prolonged use. If irritation develops, discontinued use and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peanut oil: Derma-Smoothe/FS products may contain peanut oil; use caution in peanut-sensitive individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, groin, or diaper area unless directed by health care provider. Use the least amount needed to cover the affected area; discontinue when control is achieved. If improvement is not seen within 2 weeks, reassess.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Shampoo: Has not been proven to be effective in corticosteroid responsive dermatoses other than seborrheic dermatitis of the scalp.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820081\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids may be absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress. Infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299349\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097493\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15987&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097469\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097470\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided (Reed 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760486\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth in pediatric patients; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100660\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.  Fluocinolone has low to intermediate range potency (dosage-form dependent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100662\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Dependent on formulation, amount applied, nature of skin at application site; may be increased with inflammation or occlusion </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; bile </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503158\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Considered a moderate-potency steroid (Derma-Smoothe/FS and Capex shampoo are considered to be low to medium potency); Derma-Smoothe/FS is made with 48% refined peanut oil, NF (peanut protein is &lt;0.5 ppm)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8100718\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (15 g): $44.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (15 g): $35.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (120 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar (Cream) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (375 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar (Ointment) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (375 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Synalar TS External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (1): $579.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xilapak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (1): $7,341.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Derma-Smoothe/FS Body External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $308.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Derma-Smoothe/FS Scalp External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $312.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Fluocinolone Acetonide Body External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $220.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Fluocinolone Acetonide Scalp External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (118.28 mL): $222.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (15 g): $33.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (120 g): $542.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Shampoo</b> (Capex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (120 mL): $458.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluocinolone Acetonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (60 mL): $187.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Synalar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (60 mL): $579.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961973\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adermina (CL);</li>\n      <li>Aplosyn (PH);</li>\n      <li>Bratofil (VE);</li>\n      <li>Bravoderm (ID);</li>\n      <li>Cinolon (ID);</li>\n      <li>Cortoderm (ZA);</li>\n      <li>Dermalar (IL);</li>\n      <li>Dermasolon Gel (ID);</li>\n      <li>Dermolar (AE, BH, KW, QA, SA);</li>\n      <li>Emderm (IN);</li>\n      <li>Esacinone (AE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Fluciderm (ET, ID, MY);</li>\n      <li>Flucinar (BG, CZ, DE, HN, LV, PL, VN);</li>\n      <li>Flucort (ET, IN, TW, VN);</li>\n      <li>Flucortone (TW);</li>\n      <li>Flulone (AR);</li>\n      <li>Flunolone (TW);</li>\n      <li>Flunolone-V (SG, TH);</li>\n      <li>Fluo-A (TW);</li>\n      <li>Fluociclerc (PY);</li>\n      <li>Fluocid Forte (ES);</li>\n      <li>Fluocinolona (PY);</li>\n      <li>Fluoderm (ZA);</li>\n      <li>Fluonid (MY);</li>\n      <li>Flutsynar (UA);</li>\n      <li>Fungakil (BD);</li>\n      <li>Gelargin (CZ);</li>\n      <li>Inoderm (ID);</li>\n      <li>Jellin (DE);</li>\n      <li>Localyn (IT);</li>\n      <li>Luci (IN);</li>\n      <li>Paracort (TW);</li>\n      <li>Petralar (JO, KW);</li>\n      <li>Radiocin (AE, BF, BH, BJ, CI, CY, EG, GH, GM, GN, IQ, IR, JO, KE, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, UG, YE, ZM);</li>\n      <li>Skinalar (BD, LK);</li>\n      <li>Supricort (PE);</li>\n      <li>Synalar (AE, AT, BB, BE, BF, BH, BJ, CH, CI, CY, DK, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HK, IQ, IR, IS, JO, KE, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NO, NZ, OM, PK, PT, QA, SA, SC, SD, SE, SI, SK, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Synalar Simple (UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capex shampoo (fluocinolone) [prescribing information]. Sanford, FL: Hill Dermaceuticals, Inc; February 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derma-Smoothe/FS body oil (fluocinolone) [prescribing information]. Sanford, FL: Hill Dermaceuticals, Inc; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Derma-Smoothe/FS scalp oil (fluocinolone) [prescribing information]. Sanford, FL: Hill Dermaceuticals, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar cream (fluocinolone) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals, Inc; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar ointment (fluocinolone) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals, Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synalar solution (fluocinolone) [prescribing information]. Medimetriks Pharmaceuticals, Inc; January 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15987 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8097444\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8097445\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10501531\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10503156\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8100716\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8097456\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503157\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8097502\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10503151\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8097421\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8097489\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8097474\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8097475\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820081\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299349\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8097493\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8097469\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8097470\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45760486\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8100660\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8100662\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10503158\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8100718\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961973\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15987|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluocinolone-topical-drug-information\" class=\"drug drug_general\">Fluocinolone (topical): Drug information</a></li><li><a href=\"topic.htm?path=fluocinolone-topical-patient-drug-information\" class=\"drug drug_patient\">Fluocinolone (topical): Patient drug information</a></li></ul></div></div>","javascript":null}